BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, van Meerbeeck J, Smeets P, Troisi R, Thierens H, De Vos F, Van de Wiele C. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Eur J Nucl Med Mol Imaging 2006;33:344-52. [PMID: 16333675 DOI: 10.1007/s00259-005-1954-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Buscombe J. The Future of Molecular Radiotherapy Services in the UK. Clinical Oncology 2021;33:137-43. [DOI: 10.1016/j.clon.2020.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lepareur N, Ardisson V, Noiret N, Boucher E, Raoul JL, Clément B, Garin E. Automation of labelling of Lipiodol with high-activity generator-produced 188Re. Appl Radiat Isot 2011;69:426-30. [PMID: 21106381 DOI: 10.1016/j.apradiso.2010.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
3 Das T, Chakraborty S, Sarma HD, Venkatesh M, Banerjee S. 166Ho-labeled hydroxyapatite particles: a possible agent for liver cancer therapy. Cancer Biother Radiopharm 2009;24:7-14. [PMID: 19216630 DOI: 10.1089/cbr.2008.0545] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
4 Oyen W, Bodei L, Giammarile F, Maecke H, Tennvall J, Luster M, Brans B. Targeted therapy in nuclear medicine—current status and future prospects. Annals of Oncology 2007;18:1782-92. [DOI: 10.1093/annonc/mdm111] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
5 Das T, Chakraborty S, Sarma HD, Venkatesh M, Banerjee S. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. Nucl Med Commun 2009;30:362-7. [PMID: 19282794 DOI: 10.1097/MNM.0b013e328329981a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
6 Delaunay K, Edeline J, Rolland Y, Lepareur N, Laffont S, Palard X, Bouvry C, Le Sourd S, Pracht M, Ardisson V, Noiret N, Bellissant É, Garin E. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. Eur J Nucl Med Mol Imaging 2019;46:1506-17. [DOI: 10.1007/s00259-019-04277-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
7 Boucher E, Bouguen G, Garin E, Guillygomarch A, Boudjema K, Raoul JL. Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med. 2008;49:362-366. [PMID: 18287267 DOI: 10.2967/jnumed.107.044750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
8 Sundram F. Radionuclide therapy of hepatocellular carcinoma. Biomed Imaging Interv J. 2006;2:e40. [PMID: 21614248 DOI: 10.2349/biij.2.3.e40] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
9 Oehme L, Kotzerke J. Radiobiological considerations for radioembolization with 188Re-microspheres. Eur J Nucl Med Mol Imaging 2009;36:322-5. [PMID: 19018527 DOI: 10.1007/s00259-008-0991-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N. Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres. Biomed Res Int 2018;2018:1435302. [PMID: 30687734 DOI: 10.1155/2018/1435302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
11 Subramanian S, Das T, Chakraborty S, Sarma HD, Banerjee S, Samuel G, Venkatesh M. Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study. Cancer Biother Radiopharm 2010;25:539-43. [PMID: 20849309 DOI: 10.1089/cbr.2010.0792] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
12 Jeong JM, Knapp F. Use of the Oak Ridge National Laboratory Tungsten-188/Rhenium-188 Generator for Preparation of the Rhenium-188 HDD/Lipiodol Complex for Trans-Arterial Liver Cancer Therapy. Seminars in Nuclear Medicine 2008;38:S19-29. [DOI: 10.1053/j.semnuclmed.2007.10.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
13 Nowicki ML, Cwikla JB, Sankowski AJ, Shcherbinin S, Grimmes J, Celler A, Buscombe JR, Bator A, Pech M, Mikołajczak R, Pawlak D. Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers. Med Sci Monit 2014;20:1353-62. [PMID: 25086245 DOI: 10.12659/MSM.890480] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
14 Wang SJ, Huang WS, Chuang CM, Chang CH, Lee TW, Ting G, Chen MH, Chang PM, Chao TC, Teng HW, Chao Y, Chen YM, Lin TP, Chang YJ, Chen SJ, Huang YR, Lan KL. A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. EJNMMI Res 2019;9:46. [PMID: 31119414 DOI: 10.1186/s13550-019-0509-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
15 Meléndez-Alafort L, Nadali A, Zangoni E, Banzato A, Rondina M, Rosato A, Mazzi U. Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. Nucl Med Biol 2009;36:693-701. [PMID: 19647176 DOI: 10.1016/j.nucmedbio.2009.04.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
16 Yoo RJ, Lee Y, Lee KC, Kim DW, Kim D, Choe YS, Jeong JM. KSNM60: The History of Radiopharmaceutical Sciences in Korea. Nucl Med Mol Imaging. [DOI: 10.1007/s13139-022-00744-8] [Reference Citation Analysis]
17 Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med Biol 2008;35:589-97. [PMID: 18589303 DOI: 10.1016/j.nucmedbio.2008.03.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
18 Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr. Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front Med (Lausanne) 2019;6:132. [PMID: 31259173 DOI: 10.3389/fmed.2019.00132] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 11.7] [Reference Citation Analysis]
19 He P, Guan S, Ren E, Chen H, Chen H, Peng Y, Luo B, Xiong Y, Li B, Li J, Mao J, Liu G. Precision Interventional Brachytherapy: A Promising Strategy Toward Treatment of Malignant Tumors. Front Oncol 2021;11:753286. [PMID: 34692537 DOI: 10.3389/fonc.2021.753286] [Reference Citation Analysis]
20 Liepe K, Faulhaber D, Wunderlich G, Andreeff M, Haase M, Jung R, Oehme L, Dörr W, Kotzerke J. Radiation Pneumopathy in the Rat After Intravenous Application of 188Re-Labeled Microspheres. International Journal of Radiation Oncology*Biology*Physics 2011;81:529-36. [DOI: 10.1016/j.ijrobp.2010.08.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]